Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population‐based case–control study

Abstract

Inhaled GC users had no increased risk of femur/hip fracture after adjustment for underlying disease severity. Our data suggest that, even at higher dosages, inhaled GC use is not an independent risk factor for fracture. In contrast, oral GC use was associated with an increased risk of fracture, which was not fully explained by the underlying disease severity.